Search research articles
Contact Us
Filters
Showing results (61-70 of 82) with videos related to
Page
of 9
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 19, 2009
CD8 T-cell responses against cyclin B1 in breast cancer patients with tumors overexpressing p53
Rikke Baek Sørensen, Rikke Sick Andersen, Inge Marie Svane, et al.
Breast Cancer Research and Treatment
|
January 15, 2011
Effect of adding gefitinib to neoadjuvant chemotherapy in estrogen receptor negative early breast cancer in a randomized phase II trial
Mogens Bernsdorf, Christian Ingvar, Leif Jörgensen, et al.
Breast (Edinburgh, Scotland)
|
June 16, 2018
Diagnostic challenges in clinical, radiological and histopathological tests regarding papillomatous lesions of the breast
Birgitte Bruun Rasmussen, Eva Balslev, Ib Jarle Christensen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 20, 2005
retrospective analysis of topoisomerase IIa amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil: Danish Breast Cancer Cooperative Group
Ann S Knoop, Helle Knudsen, Eva Balslev, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 23, 2024
Adjuvant Docetaxel and Cyclophosphamide With or Without Epirubicin for Early Breast Cancer: Final Analysis of the Randomized DBCG 07-READ Trial
Maj-Britt Jensen, Eva Balslev, Ann Søegaard Knoop, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 30, 2009
HER2, TOP2A, and TIMP-1 and responsiveness to adjuvant anthracycline-containing chemotherapy in high-risk breast cancer patients
Bent Ejlertsen, Maj-Britt Jensen, Kirsten V Nielsen, et al.
Oncoimmunology
|
May 24, 2021
The immune microenvironment and relation to outcome in patients with advanced breast cancer treated with docetaxel with or without gemcitabine
Elisabeth S Stovgaard, Karama Asleh, Nazia Riaz, et al.
Cancer Immunology, Immunotherapy : CII
|
February 8, 2007
Vaccination with p53 peptide-pulsed dendritic cells is associated with disease stabilization in patients with p53 expressing advanced breast cancer; monitoring of serum YKL-40 and IL-6 as response biomarkers
Inge Marie Svane, Anders E Pedersen, Julia S Johansen, et al.
Breast Cancer Research and Treatment
|
December 14, 2011
TIMP-1 in combination with HER2 and TOP2A for prediction of benefit from adjuvant anthracyclines in high-risk breast cancer patients
Pernille Braemer Hertel, Dongsheng Tu, Bent Ejlertsen, et al.
International Journal of Cancer
|
April 10, 2015
Topoisomerase-1 gene copy aberrations are frequent in patients with breast cancer
Iben Kümler, Eva Balslev, Tim S Poulsen, et al.
Page
of 9
Search research articles
Search
Showing results (61-70 of 82) with videos related to
Sort By:
Page
of 9
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 19, 2009
CD8 T-cell responses against cyclin B1 in breast cancer patients with tumors overexpressing p53
Rikke Baek Sørensen, Rikke Sick Andersen, Inge Marie Svane, et al.
Breast Cancer Research and Treatment
|
January 15, 2011
Effect of adding gefitinib to neoadjuvant chemotherapy in estrogen receptor negative early breast cancer in a randomized phase II trial
Mogens Bernsdorf, Christian Ingvar, Leif Jörgensen, et al.
Breast (Edinburgh, Scotland)
|
June 16, 2018
Diagnostic challenges in clinical, radiological and histopathological tests regarding papillomatous lesions of the breast
Birgitte Bruun Rasmussen, Eva Balslev, Ib Jarle Christensen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 20, 2005
retrospective analysis of topoisomerase IIa amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil: Danish Breast Cancer Cooperative Group
Ann S Knoop, Helle Knudsen, Eva Balslev, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 23, 2024
Adjuvant Docetaxel and Cyclophosphamide With or Without Epirubicin for Early Breast Cancer: Final Analysis of the Randomized DBCG 07-READ Trial
Maj-Britt Jensen, Eva Balslev, Ann Søegaard Knoop, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 30, 2009
HER2, TOP2A, and TIMP-1 and responsiveness to adjuvant anthracycline-containing chemotherapy in high-risk breast cancer patients
Bent Ejlertsen, Maj-Britt Jensen, Kirsten V Nielsen, et al.
Oncoimmunology
|
May 24, 2021
The immune microenvironment and relation to outcome in patients with advanced breast cancer treated with docetaxel with or without gemcitabine
Elisabeth S Stovgaard, Karama Asleh, Nazia Riaz, et al.
Cancer Immunology, Immunotherapy : CII
|
February 8, 2007
Vaccination with p53 peptide-pulsed dendritic cells is associated with disease stabilization in patients with p53 expressing advanced breast cancer; monitoring of serum YKL-40 and IL-6 as response biomarkers
Inge Marie Svane, Anders E Pedersen, Julia S Johansen, et al.
Breast Cancer Research and Treatment
|
December 14, 2011
TIMP-1 in combination with HER2 and TOP2A for prediction of benefit from adjuvant anthracyclines in high-risk breast cancer patients
Pernille Braemer Hertel, Dongsheng Tu, Bent Ejlertsen, et al.
International Journal of Cancer
|
April 10, 2015
Topoisomerase-1 gene copy aberrations are frequent in patients with breast cancer
Iben Kümler, Eva Balslev, Tim S Poulsen, et al.
Page
of 9